June 23, 2022 5:21pm
Very lucky, BSTG settled terminal death suit as Dr. Paolo Macchiarini was found criminally liable in Swedish court for causing felony bodily injury to a patient, he had fitted with one of the artificial windpipes.
With a three (3) year-old IND and multiple, and more Private Placements (PPM) that have funded WHAT?
Who or whom U.S. investors invest in this equity are backing the wrong horse or just putting lipstick on a pig?
Where did it all start; with CEO and founder David Green "ensnaring and entangling" BSTG with a terminal death suit “supplying” Paolo Macchiarini; an Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.
Scandal for the ages! Dr. Paolo Macchiarini was found criminally liable in Swedish court for causing felony bodily injury to a patient he had fitted with one of the artificial windpipes seeded with #stemcells at Karolinska Institute. He received a “conditional,” or suspended, sentence.
Any comment from BSTG, David Green, Interim CEO, Chairman and former (at time) CEO ...who introduced Paolo Macchiarini to Harvard Apparatus Regenerative Technology now Biostage (BSTG)
Even more questions of corporate attrition NEED answers … I’ve read comments on trading websites that question WHY hasn’t there been more communication from the company and when will the BSTG website be updated.
Consider the attrition rate of the past five (5) years: two (2) CEOs, one (1) CMO who became president, one (1) CFO, one (1) interim CFO who walked-out over irregularities in an audit review, three (3) controllers, a VP of Finance who left without notice and reappeared as a consultant, five (5) members of the board of directors of which three (3) were on the audit committee, three (3) other operating VPs and twenty (20) scientific employees.
Is there a pattern here … and WHO is left with biotech experience to focus the clinical trials that have YET to be initiated after an IND approval?
All the while, Biostage (BSTG) is STILL not in good standing with a “going concern” designation.